- Daniel Buckley, Senior Director & Head of Ab Cell Purification Development
Samsung Biologics is committed to helping pharma and biotech companies achieve development milestones – ensuring that a program runs smoothly and timelines are met. Building on scientific and regulatory expertise, dedicated teamwork, and thorough planning, the company continues to adapt to innovation and utilizes advanced technology to assess risks and manage challenges without compromising quality.
Samsung Biologics offers a 10-month timeline from cell line development to Investigational New Drug (IND) filing for antibodies and 12 months for complex. The company has launched proprietary technology platforms that can assess molecules and increase ex-pression as well as enhance quality and accelerate timelines.
“For every single project, our experts and scientists from each field come together to understand the unique characteristics of a client’s molecule. Based on our past development experience and after an in-depth analysis, we draw up a personalized solution depending on the client’s needs. During development, seamless communication and collaboration across teams has enabled us to promptly respond when any issue arises.”
- Suhil Chung, Senior Manager in CDO Support
Samsung Biologics also offers customized development services – SelecTailor™– whereby clients can choose from three packages that best fits their specific goals. Each package is designed to ensure maximum flexibility as clients can fine-tune their own programs by adding service options.
Utilizing pre-built modules, the company implements a highly streamlined approach, while assessing potential risks. This framework gives clients a guideline of where to start and what to expect – speeding up the process and allowing the implementation of appropriate strategies along the way.
Samsung Biologics also provides a seamless transition from development to clinical manufacturing and beyond, leveraging its track record of success in the contract manufacturing space – such as large capacity with bioreactors of multiple scale from 1,000 liters through 15,000 liters, GMP capabilities, global standard in tech transfer and raw materials procurement. The company also has vast experience in facility operations and regulatory inspections.
“As a trusted CDMO partner, we do our best to address continuously changing client needs during the course of development without any road bumps while providing full transparency to the clients along the way. Clients want us to step up in every aspect; they value our opinion in decision making when carrying out the program.”
- Jaewon Mun, Director in CDO Project Management
As competition intensifies to be the first to market, a robust development plan that maps out potential risks but commits to speed and quality from the initial stages is crucial. Samsung Biologics continues to optimize processes, train personnel, and expand its capacity with the utmost priority on client satisfaction.
The company understands that each molecule is unique, and our dedicated team can provide meticulous support at each stage of the journey to realize its full potential. Samsung Biologics is committed to delivering on our promises to clients: ensuring the success of their programs and ultimately, helping patients with unmet medical needs.
If you are a biotech seeking to outsource your project from cell line development to IND, we have extensive experience offering innovative solutions to clients. Read about our two recent partnership success stories below.
Related Contents